This application is submitted in response to RFA DK-07-012 which solicits applications from qualified investigators for the continuation and expansion of the Drug Induced Liver Injury Network (DILIN). Indiana University, one of the founder members and a top recruitment site, has robustly participated in all DILIN operations since its inception. In addition to accelerated subject recruitment, the DILIN during the next funding period will also focus on developing or supporting mechanistic and therapeutic ancillary studies, developing and validating optimal causality instruments and constructing in conjunction with NLM an authoritative hepatotoxicity database. We propose the following specific aims to meet the goals of this RFA.
Specific Aim # 1: To enroll large number of eligible adults and children with suspected DILI into ongoing DILIN prospective and retrospective studies. We propose to collect prospective and retrospective cases of suspected DILI from multiple traditional as well as unique sources in Central Indiana, each providing distinctive epidemiological facets and research potential.
Specific Aim # 2: To robustly participate in the development and the support of mechanistic (genetic and non-genetic) and therapeutic ancillary studies by investigators within and outside the DILIN. We propose to conduct a network wide therapeutic ancillary pilot study of systemic steroids in patients with well characterized DILI during the next funding period.
Specific aim # 3: To continue to participate in a robust fashion in the causality assessment of suspected DILI cases that are enrolled into our ongoing studies and to play a major role in developing and validating new causality instrument(s) that are optimal and user-friendly.
Specific aim # 4: To develop, in conjunction with stake holders, an authoritative electronic DILI database, and outreach and educational activities for practicing physicians and the public. Our role will be extensive at conceptual, methodological, operational and contextual levels.
Specific aim # 5: The objective is to develop, in conjunction with other DILIN investigators, an international consortium of DILI to facilitate exchange of ideas, standardization of nomenclature, collaborative studies and cross validation of each other's observations and discoveries.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-8 (O1))
Program Officer
Serrano, Jose
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Martinez, Melissa A; Vuppalanchi, Raj; Fontana, Robert J et al. (2015) Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol 13:369-376.e3
Hayashi, Paul H; Barnhart, Huiman X; Fontana, Robert J et al. (2015) Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int 35:1623-32
Kleiner, David E; Chalasani, Naga P; Lee, William M et al. (2014) Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59:661-70
Fontana, Robert J; Hayashi, Paul H; Gu, Jiezhun et al. (2014) Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 147:96-108.e4
Russo, Mark W; Hoofnagle, Jay H; Gu, Jiezhun et al. (2014) Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 60:679-86
Ghabril, Marwan; Fontana, Robert; Rockey, Don et al. (2013) Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience. J Clin Gastroenterol 47:553-8
Ghabril, Marwan; Bonkovsky, Herbert L; Kum, Clarissa et al. (2013) Liver injury from tumor necrosis factor-* antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 11:558-564.e3
Bell, L N; Vuppalanchi, R; Watkins, P B et al. (2012) Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther 35:600-12
Lucena, M Isabel; Molokhia, Mariam; Shen, Yufeng et al. (2011) Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141:338-47
Orman, Eric S; Conjeevaram, Hari S; Vuppalanchi, Raj et al. (2011) Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 9:517-523.e3

Showing the most recent 10 out of 25 publications